LiveKidney Commences Phase I/IIa Trial of Innovative Lupus Treatment LK-SC001 LiveKidney has initiated its Phase I/IIa clinical trial for LK-SC001, aiming to provide a groundbreaking treatment for lupus nephritis patients, marking a pivotal advancement in kidney therapies.

LiveKidney Commences Phase I/IIa Trial of Innovative Lupus Treatment LK-SC001 #USA #South_Carolina #Lupus_Nephritis #LK-SC001 #LiveKidney